NAGIOS: RODERIC FUNCIONANDO

Atherogenic Ratios in Patients with Recurrent Acute Coronary Syndrome and Receiving Statin Therapy: Clinical Usefullness as Cardiovascular Predictors

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Atherogenic Ratios in Patients with Recurrent Acute Coronary Syndrome and Receiving Statin Therapy: Clinical Usefullness as Cardiovascular Predictors

dc.contributor.author	Ferrer Civeira, Maria
dc.contributor.author	Pedro Botet, Juan
dc.contributor.author	Pintó, Xavier
dc.contributor.author	Zúñiga, Manuel
dc.contributor.author	Mangas, Alipio
dc.contributor.author	Hernández Mijares, Antonio
dc.contributor.author	Corbella, Emili
dc.contributor.author	Millán Nuñez-Cortes, Jesús
dc.date.accessioned	2015-10-07T12:23:47Z
dc.date.available	2015-10-07T12:23:47Z
dc.date.issued	2015
dc.identifier.citation	Ferrer Civeira, Maria Pedro Botet, Juan Pintó, Xavier Zúñiga, Manuel Alipio Mangas Hernandez Mijares, Antonio Corbella, Emili Millan Nuñez-Cortes, Jesús 2015 Atherogenic Ratios in Patients with Recurrent Acute Coronary Syndrome and Receiving Statin Therapy: Clinical Usefullness as Cardiovascular Predictors Journal Clinical & Experimental Cardiology 6 2 358 362
dc.identifier.uri	http://hdl.handle.net/10550/47681
dc.description.abstract	Patients who have already suffered a vascular event require more and better control of cardiovascular risk factors. Different atherogenic indexes such as TC/HDLc, LDLc/HDLc, apoB/apoA-I, LDLc/apoB and non-HDLc/HDLc have been used to follow-up the patients because of their predictive capacity of the lipid profile. The aim of this study was to evaluate atherogenic ratios as a marker of the lipid residual risk in high-risk patients receiving statin therapy and to know the changes produced by previous lipid-lowering drugs treatment for a previous coronary event. The study including patients admitted to coronary care units of six Spanish tertiary hospitals for Acute Coronary Syndrome (ACS). A total of 633 ACS patients were included; of these, 478 (75.8%) had presented a myocardial infarction and 153 (24.2%) angina. A previous ACS had occurred in 43.1% of cases, and was the first episode in 56.9% of the studied patients. Among patients with known ischemic heart disease, 187 (52.2%) were receiving lipid-lowering drugs, mainlystatins (182 patients, 50.7%). Of those with a first ACS, 59 (21.7%) were on lipid-lowering drugs: 55 (20.1%) statins and 4 (1.7%) fibrates. Patients with recurrent ACS had similar triglyceride and HDLc levels, but significantly lower total cholesterol and LDLc concentrations compared with those presenting the first ACS. Patients with recurrent ACS had significantly lower non-HDLc levels, TC/HDLc and LDLc/HDLc, but higher HDLc/TC and HDLc/LDLc ratios compared with first ACS patients. In patients taking statins the lipid residual vascular risk was related with the persistence of cardiovascular risk factors, and related with lipid profile with dyslipemia no-LDL dependent. So, we can conclude that the correction of lipid profile by statin is not per se sufficient to control cardiovascular risk.
dc.language.iso	eng
dc.relation.ispartof	Journal Clinical & Experimental Cardiology, 2015, vol. 6, num. 2, p. 358-362
dc.subject	Cor Malalties
dc.title	Atherogenic Ratios in Patients with Recurrent Acute Coronary Syndrome and Receiving Statin Therapy: Clinical Usefullness as Cardiovascular Predictors
dc.type	journal article	es_ES
dc.date.updated	2015-10-07T12:23:47Z
dc.identifier.doi	10.4172/2155-9880.1000358
dc.identifier.idgrec	103639
dc.rights.accessRights	open access	es_ES